Atopic dermatitis in a 2-year-old child treated with individualised homoeopathic medicine: A case report

2021 ◽  
Vol 4 ◽  
pp. 86-93 ◽  
Author(s):  
Sanjukta Mandal ◽  
Bikash Biswas ◽  
Jahir Abbas
Keyword(s):  
Allergic Rhinitis ◽  
Early Childhood ◽  
Atopic Dermatitis ◽  
Case Report ◽  
Adverse Effects ◽  
Marked Improvement ◽  
Skin Condition ◽  
Subjective Symptoms ◽  
Rapid Improvement ◽  
Pruritic Skin

Atopic dermatitis (AD) is a chronic, relapsing pruritic skin condition which is accompanied by inflammation of the affected parts. It usually develops during early childhood and has a predilection for the skin flexures. Approximately 70% of cases start before the age of 5 years: Only 10% begin in adulthood. Asthma and allergic rhinitis are comorbid in most cases. This is a case report of a 2-year-old child who presented with reddish elevated papular eruptions on the skin with severe itching. After thorough case taking and examination, the diagnosis was AD, based on the Hanifin and Rajka criteria. The patient underwent individualised homoeopathic treatment. In subsequent follow-ups, the patient’s improvement was monitored using the PO-SCORAD scale and the subjective symptoms. Marked improvement was noted within a few months. Homoeopathic treatment is effective in these cases to yield rapid improvement without any adverse effects.

scholarly journals Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature

2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Samantha E. Jacobs ◽  
Deborah Saez-Lacy ◽  
Walter Wynkoop ◽  
Thomas J. Walsh
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Invasive Aspergillosis ◽  
Successful Treatment ◽  
Marked Improvement ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Primary Therapy ◽  
Review Of The Literature ◽  
First Report

Abstract Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA.

scholarly journals Significance of the epidermal barrier and sensitisation to household allergens to the development of atopic march for primary prevention

2018 ◽  
Vol 17 (2) ◽  
pp. 114-120
Author(s):  
E. E. Varlamov ◽  
A. N. Pampura ◽  
A. N. Asmanov
Keyword(s):  
Allergic Rhinitis ◽  
Early Childhood ◽  
Atopic Dermatitis ◽  
Primary Prevention ◽  
Bronchial Asthma ◽  
Allergic Diseases ◽  
The State ◽  
Older Age ◽  
Epidermal Barrier ◽  
Atopic March

Atopic march is a variant flowing of atopia that begins in early childhood as atopic dermatitis, then developinto other allergic diseases (bronchial asthma, allergic rhinitis) at an older age. The state of the epidermal barrier and sensitization to inhaled allergens are considered as predictors for the development of atopic march. Data on the importance of these factors in the development of atopic march and information about possible approaches to prevention are presented in this article.

scholarly journals Prurigo Nodularis and Hodgkin’s Lymphoma: A Rare Association

2019 ◽  
pp. 59
Author(s):  
Zher Lin Go ◽  
Low Qin Jian ◽  
Nurul Aisyah Abd Rahman ◽  
Ng Ling Fong ◽  
Lau Ngee Siang ◽  
...  
Keyword(s):  
Case Report ◽  
General Practitioners ◽  
Topical Treatment ◽  
Marked Improvement ◽  
Systemic Disease ◽  
Skin Condition ◽  
Systemic Diseases ◽  
Prurigo Nodularis ◽  
Rare Association ◽  
Systemic Symptoms

Prurigo nodularis (PN) is an uncommon skin condition known to be associated with underlying systemic diseases. This case report is about PN secondary to underlying Hodgkin’s lymphoma. A 30-year-old man presented with this skin condition three months before lymphadenopathy and systemic symptoms due to lymphoma. He had made multiple visits to general practitioners for the disturbing rash, given multiple courses of topical treatment without relief. His PN showed marked improvement after initiation of chemotherapy. This case reminds that an unexplained skin condition should prompt clinicians for investigating for an underlying systemic disease. This case, to our knowledge, is the first Hodgkin’s lymphoma-associated prurigo nodularis reported in Malaysia.

Atopic dermatitis: new horizons of therapy

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler
Keyword(s):  
Blood Pressure ◽  
Immune Response ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Targeted Therapy ◽  
Inflammatory Response ◽  
Bronchial Asthma ◽  
New Horizons ◽  
The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Questionnaire Survey of Female Patients with Atopic Dermatitis Regarding Genital Skin Condition

2010 ◽  
Vol 72 (4) ◽  
pp. 385-389
Author(s):  
Miwa KOBAYASHI ◽  
Yoshiki TOKURA ◽  
Noriko SATO ◽  
Yutaka TAKAGI ◽  
Takashi KITAHARA ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Questionnaire Survey ◽  
Skin Condition ◽  
Female Patients

scholarly journals Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report

2021 ◽  
pp. 379-383
Author(s):  
Meghan L. McPhie ◽  
Kevin Y.M. Ren ◽  
J. Michael Hendry ◽  
Sonja Molin ◽  
Thomas Herzinger
Keyword(s):  
Case Report ◽  
Hepatitis C ◽  
Adverse Effects ◽  
Hypersensitivity Reaction ◽  
Allergic Reaction ◽  
Delayed Type Hypersensitivity ◽  
Histological Features

Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with the initiation of ledipasvir/sofosbuvir treatment for his hepatitis C. Clinical and histological features were consistent with a delayed-type hypersensitivity reaction to red ink.

Inhibition of IL-13: A New Pathway for Atopic Dermatitis

2020 ◽  
pp. 120347542098255
Author(s):  
Kayadri Ratnarajah ◽  
Michelle Le ◽  
Anastasiya Muntyanu ◽  
Steve Mathieu ◽  
Simon Nigen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Atopic Dermatitis ◽  
Severity Index ◽  
Severe Atopic Dermatitis ◽  
Treatment Alternative ◽  
Control Groups ◽  
Rapid Improvement ◽  
Common Receptor ◽  
The Common ◽  
And Control

Dupilumab, a monoclonal antibody against the common receptor of interleukin (IL)-4 and IL-13, was the first biologic therapy approved in Canada for treatment of moderate-to-severe atopic dermatitis (AD). While it is considered safe and effective, dupilumab is not universally effective and 8%-38% of patients develop conjunctivitis, while some patients develop head and neck dermatitis. Thus, new therapeutic options are warranted. While both IL-4 and IL-13 play important roles in the pathogenesis of AD, it has been recently demonstrated that IL-13 is the primary upregulated cytokine in AD skin biopsy samples. A placebo-controlled phase 2b clinical trial evaluating the efficacy and safety of lebrikizumab, an IL-13 inhibitor, in AD demonstrated that, at 16 weeks, Eczema Area and Severity Index (EASI) 75 and Investigator’s Global Assessment (IGA) 0/1 were achieved by 60.6% and 44.6% of patients taking lebrikizumab at its highest dose (vs 24.3% and 15.3% of patients taking placebo, respectively). Moreover, treatment with lebrikizumab was associated with rapid improvement of pruritus and low rates of conjunctivitis (1.4%-3.8%). Another IL-13 monoclonal antibody, tralokinumab, was evaluated for safety and efficacy in moderate-to-severe AD. By week 12, among adults receiving 300 mg tralokinumab, 42.5% achieved EASI-75 and 26.7% achieved IGA 0/1 score (vs 15.5% and 11.8% in the placebo group, respectively). Both lebrikizumab and tralokinumab demonstrated acceptable safety profiles in AD (and non-AD) trials with adverse events often being comparable between treatment and control groups. Thus, IL-13 inhibitors may provide a safe and effective treatment alternative for patients with moderate-to-severe AD.

Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma

2021 ◽  
Vol 147 (2) ◽  
pp. AB28
Author(s):  
Jonathan Spergel ◽  
Michael Blaiss ◽  
Peter Lio ◽  
Aharon Kessel ◽  
Liza Takiya ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Efficacy And Safety

scholarly journals Plaque erosion causing ST-elevation myocardial infarction after consumption of cannabis and N2O in a 27-year old man: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sarah Bär ◽  
Fabien Praz ◽  
Lorenz Räber
Keyword(s):  
Myocardial Infarction ◽  
Case Report ◽  
Adverse Effects ◽  
Cardiovascular Effects ◽  
Drug Eluting Stent ◽  
Culprit Lesion ◽  
Vascular Events ◽  
The Public ◽  
Plaque Erosion ◽  
First Case

Abstract Background The recreational drugs cannabis and nitrous oxide (N2O) are known for pro-atherogenic effects and are associated with an elevated risk of myocardial infarction. These cardiovascular effects might be underestimated by the public. Culprit-lesion composition of myocardial infarctions associated with cannabis and N2O has been unknown so far. This case report aims to raise the awareness of the adverse cardiovascular effects of cannabis and N2O and reports, for the first time, optical coherence tomography (OCT) findings of the culprit lesion. Case presentation This is a case report of a 27-year old man with anterior ST-segment-elevation myocardial infarction (STEMI) after intoxication with cannabis and N2O. Coronary angiography and OCT revealed plaque erosion with subsequent subtotal thrombotic occlusion of the left anterior descending artery that was successfully treated with 1 drug-eluting stent. The patient was symptom free at 6 months follow-up and had been able to abstain from drug consumption. Conclusions This is the first case to demonstrate the association between cannabis and N2O abuse and plaque erosion on OCT in a young man with STEMI. In contrast to smoking, whose adverse effects are well-known, the cardiovascular effects of cannabis and N2O might be underestimated. These adverse effects should gain more awareness in the public to prevent early vascular events in young adults.

Sign in / Sign up

Export Citation Format

Share Document